3DM Inc. Invited to Present on Orthopedic & Cardiac Regeneration at Windhover Convergence: Drug Device Conference

Cambridge , Mass. – February 21, 2005 – 3DM Inc. has been invited to present at the Windhover Information Inc. Convergence Summit, taking place in Pittsburgh, PA on March 21-23, 2005. 3DM will join other companies such as Boston Scientific, Medtronic, J&J, Integra, SurModics, Kensey Nash, and Angiotech in presenting the latest roadmap for medical therapies based on combinations of drugs, stem cells and medical devices. Applications across orthopedics, cardiology, regenerative medicine, oncology and neurosurgery stand to benefit from these combinations.

“This conference comes at an exciting time in the convergence of medical devices paired with drug and biologic therapies. Drug eluting stents have pioneered this area and improved interventional cardiology, but we are only at the beginning of this important trend,” stated Zen Chu, President and co-founder of 3DM Inc.

“Just this month, the latest research from Dr. Richard Lee’s lab at Harvard Medical School has been published in Circulation, with promising indications for using PuraMatrix synthetic peptide hydrogels for angiogenesis and cardiac regeneration. ” [ Davis, ME, Motion, JPM, Narmoneva, D., Takahashi, T., Hakuno, D., Kamm, RD, Zhang, S., Lee, RT. Injectable Self-Assembling Peptide Nanofibers Create Intramyocardial Microenvironments for Endothelial Cells. Circulation 111:442-450 (2005).]

About PuraMatrix

PuraMatrix Synthetic Peptide Hydrogels are the best-selling synthetic scaffolds for cell culture and bioproduction research, and have won numerous scientific awards. PuraMatrix gels consist of smart polymers, self-assembling in cell culture or in vivo to create biocompatible nanofiber scaffolds to facilitate healthy cell growth and tissue regeneration. PuraMatrix is currently in animal testing for orthopedics, cardiac and other medical device and drug delivery applications. PuraMatrix is used by most of the leading pharmaceutical, biotechnology and academic laboratories and has been featured in over twenty premier scientific journal publications. R&D Magazine recently awarded PuraMatrix its 42nd annual R&D 100 Prize as one of the most significant new products to impact life science and medical research.

About 3DM Inc.

3DM is a privately-held specialty biomaterials and medical device company headquartered in Cambridge, Massachusetts. 3DM has partnered with BD Biosciences for marketing PuraMatrix worldwide to the life science research and drug discovery communities. 3DM is further developing their self-assembling peptide hydrogels as medical devices in orthopedics, cardiovascular therapies and drug delivery applications. The patented technology, exclusively licensed from Massachusetts Institute of Technology, was pioneered at MIT through the work and expertise of Drs. Shuguang Zhang, Alan Grodzinsky, Robert Langer, Alexander Rich, Carlos Semino and Lisa Spirio.

Source: 3DM Inc.
               puramatrix.com

Contact: Zen Chu , President
                877-430-9595 contact@puramatrix.com